Gilead Sciences (GILD) Cash from Financing Activities (2009 - 2026)

Gilead Sciences has reported Cash from Financing Activities for 18 years, with the latest figure at -$4.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 23.73% year-over-year to -$4.2 billion; the trailing twelve-month figure through Mar 2026 stood at -$8.6 billion (down 55.66% YoY), and the FY2025 full-year result was -$7.7 billion, down 125.6% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$4.2 billion, down from -$1.3 billion in the prior quarter.
• The five-year high for Cash from Financing Activities was $2.3 billion in Q4 2024, with the low at -$4.2 billion in Q1 2026.
• Historically, Cash from Financing Activities has averaged -$1.6 billion across 5 years, with a median of -$1.5 billion in 2025.
• The largest YoY upside for Cash from Financing Activities was 305.64% in 2024 against a maximum downside of 168.21% in 2024.
• Gilead Sciences' Cash from Financing Activities stood at -$1.6 billion in 2022, then gained by 29.28% to -$1.1 billion in 2023, then soared by 305.64% to $2.3 billion in 2024, then sank by 155.88% to -$1.3 billion in 2025, then plunged by 235.63% to -$4.2 billion in 2026.
• The last three Cash from Financing Activities figures came in at -$4.2 billion (Q1 2026), -$1.3 billion (Q4 2025), and -$1.5 billion (Q3 2025), per Business Quant data.